Paula Alves, CEO of iBET, was interviewed on the national radio station TSF about current progresses, challenges and perspectives on Vaccine Development.
Click here to listen the full interview (in Portuguese).
Selected interview highlights:
- Technologies required for the production of vaccines are, in general, more complex than those employed in drug development through chemical synthesis.
- Cell-based vaccines require living cells to produce vaccine’s antigens. Thus, [production time] depends on cell metabolism and growth rate.
- The production of mRNA-based vaccines is cell-free. Challenges are mostly related to RNA purification, production and scale-up and RNA encapsulation processes.
- Training people in vaccine manufacturing is time-demanding and requires close collaboration between different players such as industry, R&D institutes and universities.
Interested in vaccine development? Click here to learn more about iBET work on this exciting field.